drugset / Trial / NCT04422678
The Safety & Efficacy of Imatinib for the Treatment of SARS-COV-2 Induced Pneumonia
Phase 3
Unknown
30 enrolled
Alexandria University
Science,Technology & Innovation Funding Authority, Egypt · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized controlled pilot study on the safety \& efficacy of imatinib for the treatment of patient with moderate to severe SARS-COV-2 induced pneumonia.
Timeline
- Start
- 2020-06
- Primary completion
- 2020-09
- Completion
- 2020-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 200 mg | Oral |
| Subject | Imatinib | Small molecule | 400 mg | Oral |